Navigation Links
Onyx Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
Date:9/2/2009

EMERYVILLE, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at two healthcare conferences in September.

Robert W. Baird & Co. 2009 Health Care Conference

Onyx will present at the Robert W. Baird & Co. 2009 Health Care Conference in New York, New York, on September 9, 2009 at 9:30 a.m. Eastern Time.

Thomas Weisel Partners Healthcare Conference

Subsequently, Onyx will present at the Thomas Weisel Partners Healthcare Conference in Boston, Massachusetts, on September 10, 2009 at 12:55 p.m. Eastern Time.

Interested parties may access a live webcast of both presentations on our website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentations will be available one hour following the conclusion of the presentations through October 9, 2009.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar((R)), a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit the company's website at www.onyxpharm.com.

Nexavar((R)) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16, 2009
2. Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
3. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
4. Jiangbo Pharmaceuticals to Present at Rodman & Renshaw Annual Global Investment Conference
5. Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference
6. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
7. Raptor Pharmaceuticals Schedules 2009 Annual Meeting of Stockholders
8. Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
9. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
10. EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
11. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... , Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... operational results for the three months ended December 31, 2016. ... -based life sciences and diagnostics company that develops and commercializes ... ... to build on the commercial milestones achieved in fiscal 2016," ...
(Date:2/21/2017)... ... February 21, 2017 , ... Vortex Biosciences announced ... automated benchtop system for collecting intact circulating tumor cells (CTCs) that are shed ... Medicine Tri Conference (Tri-Con) Annual Meeting 2017 (February 19–24 San Francisco). , The ...
(Date:2/21/2017)... ... 21, 2017 , ... Cancer diagnostics workflow solution provider Inspirata, ... team to lead the development and commercialization of its Cancer Information Data Trust ... and treatment of cancer. The CIDT addresses the need for curated and structured ...
(Date:2/21/2017)... ... February 21, 2017 , ... With ... operational capacity with its strategic internal leadership to provide clients with best ... operational management. With office locations in North Carolina, Massachusetts, Ohio, Illinois, ...
Breaking Biology Technology:
(Date:1/31/2017)...  Spero Therapeutics, LLC, a biopharmaceutical company founded ... bacterial infections, today announced it has acquired a ... Bono Bio Ltd (PBB) to bolster its pipeline ... of Gram-negative bacteria.   The assets acquired have been ... group company. "The acquisition of these ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm Reports ... the laboratory use of nuclear magnetic resonance spectroscopy ... end-users and profiled current practices, developments, trends and ... well as growth and opportunities. These areas include ... NMR instruments, needs and innovation requirements, hyphenated NMR ...
(Date:1/19/2017)... , Jan. 19, 2017 ... user experience and security for consumer electronics, and ... payment processing systems and cybersecurity solutions, today announced ... enterprises and financial institutions worldwide to bolster security ... the end-to-end secure user authentication platforms they offer, ...
Breaking Biology News(10 mins):